Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gore’s TAG Thoracic Endograft Is First To Go Before FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

A favorable recommendation by FDA's Circulatory System Devices Panel would place W.L. Gore one step closer to becoming the first firm with U.S. market approval for a thoracic aortic aneurysm endograft

You may also be interested in...



Panel Critiques TAG Graft Study Size, But Deems Approval “Common Sense”

The appeal of WL Gore's TAG thoractic endograft as a less-invasive alternative to open-heart surgery swayed FDA panelists to recommend device approval Jan. 13

Panel Critiques TAG Graft Study Size, But Deems Approval “Common Sense”

The appeal of WL Gore's TAG thoractic endograft as a less-invasive alternative to open-heart surgery swayed FDA panelists to recommend device approval Jan. 13

FDA Relaxes AAA Panel Meeting Criteria; Thoracic Endograft Approvals Lag

Abdominal aortic aneurysm endograft applications will no longer require advisory panel review, unless new issues arise in the course of FDA's premarket evaluation

Related Content

UsernamePublicRestriction

Register

MT021409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel